Twist Bioscience Corp — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 55/100
What the filing says
Twist reported Q3 FY26 revenue of $118.4M (23% YoY growth; beat implied guidance), raising full-year revenue guidance to $456–$457M (from $442–$447M, +$12M midpoint). Gross margin improved to 52.8% (up 120 bps sequentially). However, net loss widened to $35.1M (vs. $20.4M net income in Q3 FY25, which benefited from $48.8M Atlas Data Storage spin-out gain). Adjusted EBITDA was $(11.3)M (vs. $(8.0)M in Q3 FY25). Company reiterates Q4 FY26 adjusted EBITDA breakeven target. Cash position: $167M.
Why this rating
Strong organic growth (23% YoY, 14 consecutive quarters up) and margin expansion are material for a $2.3B biotech. Guidance raise of ~$12M (~0.5% of $2.3B market cap) is modest but confirms demand. Path to EBITDA breakeven is strategically important. Offset by worsening GAAP profitability and high SG&A growth ($80.7M vs. $63.4M YoY), raising execution risk on margin targets.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.